About OncoSec Medical (NASDAQ:ONCS)
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response in Phase 1 and 2 clinical trials for metastatic melanoma and triple-negative breast cancer. The company has also completed Phase II studies in metastatic melanoma (OMS-I100) and merkel cell carcinoma (OMS-I110). OncoSec Medical Incorporated has an investigator-sponsored clinical trial with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte (OMS-I102); and a clinical trial collaboration and drug supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of its ImmuoPulse IL-12 with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a registration-directed Phase 2b clinical trial referred to as PISCES. This trial would evaluate the combination of therapies in patients with unresectable metastatic melanoma who have progressed. It also has a research collaboration with Avacta Group plc for gene delivery of therapeutic affimers. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONCS
CUSIPN/A
Phone855-662-6732
Debt
Debt-to-Equity RatioN/A
Current Ratio6.73%
Quick Ratio6.73%
Price-To-Earnings
Trailing P/E Ratio-1.58
Forward P/E Ratio-2.29
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book3.41
Profitability
EPS (Most Recent Fiscal Year)($1.06)
Net Income$-21,440,000.00
Net MarginsN/A
Return on Equity-168.58%
Return on Assets-129.10%
Miscellaneous
Employees35
Outstanding Shares51,480,000
OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions
What is OncoSec Medical's stock symbol?
OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."
How were OncoSec Medical's earnings last quarter?
OncoSec Medical (NASDAQ:ONCS) announced its earnings results on Friday, March, 9th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.05. View OncoSec Medical's Earnings History.
When is OncoSec Medical's next earnings date?
What price target have analysts set for ONCS?
5 analysts have issued 12 month target prices for OncoSec Medical's shares. Their predictions range from $4.00 to $6.00. On average, they anticipate OncoSec Medical's share price to reach $5.00 in the next twelve months. View Analyst Ratings for OncoSec Medical.
What are Wall Street analysts saying about OncoSec Medical stock?
Here are some recent quotes from research analysts about OncoSec Medical stock:
- 1. Maxim Group analysts commented, "Oncosec announced that the P2b study (PISCES/KEYNOTE-695) in late-stage melanoma evaluating TAVO (DNA-based IL-12, intratumoral) + Keytruda has dosed the first patient." (12/14/2017)
- 2. HC Wainwright analysts commented, "We believe preliminary interim data—based on the first 16-20 patients—could be reported in late 2017 or early 2018. Management have indicated that an ORR of at least 30% would be considered a success for the PISCES study. We note that positive results from the interim analysis may allow the company to apply for Breakthrough Therapy designation in patients who have failed anti- PD-1 monotherapies. In addition, OncoSec may report 24-month follow- up data from the Phase 2 investigator-sponsored trial later this year. In the wake of this update, we reiterate our Buy rating and $6 price target. 43% ORR in Phase 2 combo trial. A prior investigator-sponsored Phase 2 combo study of ImmunoPulse IL-12 and Keytruda in 22 metastatic melanoma patients reported positive data. These patients were predicted to have low likelihoods of response to anti-PD-1 monotherapies based on biomarker assays. The results showed a 43% (9/21) ORR at 24 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. There were 24% (5/21) complete responders and 19% (4/22) partial responders. Of note, nine out of the 22 patients enrolled had prior checkpoint inhibitor therapy; ORR for this subset of patients was 33% (3/9). The data showed that intra-tumoral electroporation of interleukin-12 DNA, combined with pembrolizumab, can effectively alter the tumor microenvironment and increase tumor- specific CD8+ T-cells, which drive a systemic anti-tumor immune response. The combo therapy had an acceptable safety profile and was well tolerated." (6/2/2017)
Are investors shorting OncoSec Medical?
OncoSec Medical saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 3,134,350 shares, an increase of 49.3% from the March 15th total of 2,099,058 shares. Based on an average daily volume of 1,583,801 shares, the short-interest ratio is presently 2.0 days. Currently, 6.2% of the company's shares are short sold.
Who are some of OncoSec Medical's key competitors?
Some companies that are related to OncoSec Medical include Newron Pharmaceuticals (NWPHF), Teligent (TLGT), Aeglea Bio Therapeutics (AGLE), Tetraphase Pharmaceuticals (TTPH), Acer Therapeutics (ACER), Sierra Oncology (SRRA), BioXcel Therapeutics (BTAI), Zynerba Pharmaceuticals (ZYNE), Aldeyra Therapeutics (ALDX), Affimed (AFMD), BioDelivery Sciences International (BDSI), Galectin Therapeutics (GALT), Checkpoint Therapeutics (CKPT), Axovant Sciences (AXON), Adamis Pharmaceuticals (ADMP), OncoMed Pharmaceuticals (OMED), Otonomy (OTIC) and AcelRx Pharmaceuticals (ACRX).
Who are OncoSec Medical's key executives?
OncoSec Medical's management team includes the folowing people:
- Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)
- Mr. Punit S. Dhillon BA, Co-Founder, Pres & Director (Age 38)
- Mr. Richard B. Slansky, CFO & Sec. (Age 60)
- Dr. Sharron Gargosky Ph.D., Chief Clinical & Regulatory Officer (Age 54)
- Mr. Daniel J. O'Connor J.D., CEO & Director (Age 54)
Has OncoSec Medical been receiving favorable news coverage?
News coverage about ONCS stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. OncoSec Medical earned a media sentiment score of 0.12 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 48.56 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of OncoSec Medical?
Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoSec Medical's stock price today?
One share of ONCS stock can currently be purchased for approximately $1.66.
How big of a company is OncoSec Medical?
OncoSec Medical has a market capitalization of $84.43 million. The biotechnology company earns $-21,440,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. OncoSec Medical employs 35 workers across the globe.
How can I contact OncoSec Medical?
OncoSec Medical's mailing address is 5820 NANCY RIDGE DRIVE, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]
MarketBeat Community Rating for OncoSec Medical (ONCS)
MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote "Outperform" if you believe ONCS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days.
OncoSec Medical (NASDAQ:ONCS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for OncoSec Medical in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 199.40%. The high price target for ONCS is $6.00 and the low price target for ONCS is $4.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.00 | $5.00 | $5.3333 | $5.3333 |
| Price Target Upside: | 199.40% upside | 177.78% upside | 152.76% upside | 433.33% upside |
OncoSec Medical (NASDAQ:ONCS) Consensus Price Target History
OncoSec Medical (NASDAQ:ONCS) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
OncoSec Medical (NASDAQ:ONCS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
OncoSec Medical (NASDAQ ONCS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 8.72%
OncoSec Medical (NASDAQ ONCS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/6/2018 | Punit Dhillon | President | Buy | 3,000 | $0.88 | $2,640.00 | |  |
| 2/5/2018 | Daniel J O'connor | CEO | Buy | 16,667 | $1.50 | $25,000.50 | 16,667 | |
| 7/31/2017 | Punit Dhillon | Insider | Buy | 3,000 | $0.88 | $2,640.00 | | |
| 1/31/2017 | Punit Dhillon | Insider | Buy | 3,000 | $0.99 | $2,970.00 | | |
| 10/16/2015 | Punit Dhillon | CEO | Buy | 10,000 | $4.25 | $42,500.00 | 100 | |
| 6/10/2015 | Punit Dhillon | CEO | Buy | 2,500 | $6.74 | $16,850.00 | | |
| 3/20/2014 | Anthony E Maida III | Director | Buy | 22,800 | $0.81 | $18,468.00 | | |
| 3/19/2014 | Punit Dhillon | CEO | Buy | 50,000 | $0.80 | $40,000.00 | | |
(Data available from 1/1/2013 forward)
OncoSec Medical (NASDAQ ONCS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | OncoSec Provides Highlights from Research Reception at AACR Annual Meeting 2018
finance.yahoo.com - April 16 at 5:24 PM |
 | OncoSec Medical (ONCS) Given a $5.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - April 16 at 1:21 PM |
| OncoSec Medical (ONCS) Short Interest Update
www.americanbankingnews.com - April 14 at 2:27 AM |
| OncoSec Medical (ONCS) Expected to Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - April 9 at 5:22 PM |
| OncoSec Medical (ONCS) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 8 at 11:17 AM |
| OncoSec to Host Research Reception During the 2018 American Association of Cancer Research Annual Meeting
finance.yahoo.com - April 3 at 8:24 AM |
| OncoSec Medical (ONCS) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - April 1 at 12:08 AM |
| OncoSec Medical Inc (ONCS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 31 at 7:42 AM |
 | Biotech Market Poised to Reach 2015 Highs
www.finanznachrichten.de - March 27 at 8:28 AM |
 | What's Happening with These Biotech Stocks? -- OncoSec Medical, OvaScience, Pacific Biosciences of California, and ... - PR Newswire (press release)
www.prnewswire.com - March 22 at 8:27 AM |
| OncoSec Announces Strategic Relocation Of Office And Laboratories
finance.yahoo.com - March 20 at 8:28 AM |
| OncoSec To Present At The Oppenheimer's 28th Annual Healthcare Conference
finance.yahoo.com - March 16 at 8:21 AM |
| Maxim Group Analysts Give OncoSec Medical (ONCS) a $5.00 Price Target
www.americanbankingnews.com - March 15 at 4:54 PM |
| OncoSec's Intratumoral IL-12 In Metastatic Triple Negative Breast Cancer (TNBC) Selected For Oral Poster ... - PR Newswire (press release)
www.prnewswire.com - March 15 at 8:17 AM |
 | OncoSec (ONCS) Says Intratumoral IL-12 In Metastatic TNBC Selected For Oral Poster Presentation at AACR - StreetInsider.com
www.streetinsider.com - March 15 at 8:17 AM |
| OncoSec's Intratumoral IL-12 In Metastatic Triple Negative Breast Cancer (TNBC) Selected For Oral Poster Presentation At The American Association For Cancer Research (AACR) Annual Meeting 2018
finance.yahoo.com - March 15 at 8:17 AM |
| OncoSec Announces Publication In Nature Gene Therapy Demonstrating Efficacy Of IL-12 Intratumoral Gene ... - PR Newswire (press release)
www.prnewswire.com - March 12 at 9:16 AM |
| OncoSec Announces Publication In Nature Gene Therapy Demonstrating Efficacy Of IL-12 Intratumoral Gene Electrotransfer
finance.yahoo.com - March 12 at 9:16 AM |
| Critical Review: AEterna Zentaris (AEZS) vs. OncoSec Medical (ONCS)
www.americanbankingnews.com - March 10 at 3:34 AM |
| Zacks: Brokerages Expect OncoSec Medical Inc (ONCS) Will Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - March 6 at 1:19 PM |
| OncoSec Medical Inc (ONCS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 6 at 10:48 AM |
| OncoSec Medical Inc (ONCS) Short Interest Update
www.americanbankingnews.com - March 4 at 2:56 AM |
| OncoSec Medical Inc (ONCS) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - February 17 at 7:14 PM |
| OncoSec Medical (ONCS) Coverage Initiated at Piper Jaffray Companies
www.americanbankingnews.com - February 10 at 10:54 PM |
| OncoSec Medical Inc (ONCS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 9 at 10:12 AM |
| OncoSec Medical Inc (ONCS) CEO Acquires $25,000.50 in Stock
www.americanbankingnews.com - February 6 at 12:23 PM |
| OncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common Stock
finance.yahoo.com - February 6 at 9:33 AM |
| OncoSec Medical Incorporated Prices $20.0 Million Public Offering of Common Stock
finance.yahoo.com - February 1 at 9:40 AM |
| OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 1 at 9:40 AM |
| Brokerages Anticipate OncoSec Medical Inc (ONCS) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - January 31 at 9:10 PM |
 | Avacta, OncoSec to Collaborate to Combine Avacta's Affimer Protein Platform with OncoSec's Gene Delivery ... - Benzinga
www.benzinga.com - January 22 at 8:06 AM |
| A Peek Into The Markets: US Stock Futures Drop After Government Shutdown - Benzinga
www.benzinga.com - January 22 at 8:06 AM |
| Avacta, OncoSec to Collaborate to Combine Avacta's Affimer Protein Platform with OncoSec's Gene Delivery Technology ImmunoPulse
finance.yahoo.com - January 22 at 8:06 AM |
| Avacta, OncoSec to Collaborate to Combine Avacta's Affimer Protein Platform with OncoSec's Gene Delivery Technology ImmunoPulse
feeds.benzinga.com - January 22 at 7:20 AM |
| OncoSec Medical (ONCS) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - January 20 at 1:58 PM |
| OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study
finance.yahoo.com - January 18 at 11:14 AM |
| OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors
finance.yahoo.com - January 16 at 10:17 AM |
| Analysts Anticipate OncoSec Medical Inc (ONCS) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - January 14 at 11:06 PM |
| Oncosec Medical (ONCS) Provides 2018 Business Outlook - StreetInsider.com
www.streetinsider.com - January 3 at 9:25 AM |
| OncoSec Provides 2018 Business Outlook
finance.yahoo.com - January 3 at 9:25 AM |
| OncoSec Medical (ONCS) vs. Nektar Therapeutics (NKTR) Critical Survey
www.americanbankingnews.com - December 29 at 11:50 AM |
| OncoSec Medical Inc (ONCS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 22 at 3:58 AM |
| OncoSec Medical (ONCS) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - December 15 at 12:04 PM |
| OncoSec Medical (ONCS) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - December 14 at 12:34 PM |
| OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab
finance.yahoo.com - December 14 at 10:25 AM |
| Zacks: Analysts Expect OncoSec Medical Inc (ONCS) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - December 11 at 11:22 PM |
| OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer - PR Newswire (press release)
www.prnewswire.com - December 5 at 11:59 AM |
| OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
finance.yahoo.com - December 5 at 11:59 AM |
| OncoSec Medical (ONCS) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - December 2 at 10:36 PM |
| OncoSec Medical (ONCS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 29 at 1:44 AM |
OncoSec Medical (NASDAQ:ONCS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
OncoSec Medical (NASDAQ:ONCS) Income Statement, Balance Sheet and Cash Flow Statement
OncoSec Medical (NASDAQ ONCS) Stock Chart for Thursday, April, 19, 2018
Loading chart…
